Cochrane · systematic review · CD005052
Shengmai (a traditional Chinese herbal medicine) for heart failure
Zhou Qin, Qin Wen-Zhe, Liu Shuai-Bin, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
19
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 6 · 31.6%Very low 4 · 21.1%Low 9 · 47.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyShengmai plus usual treatment compared to usual treatment alone for heart failure
Population: patients with heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Shengmai plus usual treatment vs usual treatment alone | no estimate extracted | 11 studies · 858 participants | Ungraded |
Lack of improvement in heart failure (NYHA class improved < I class or worsening of heart failure) NYHA classification grading of cardiac function Shengmai plus usual treatment vs usual treatment alone | RR 0.37 [0.26, 0.51] | 10 studies · 672 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects Shengmai plus usual treatment vs usual treatment alone | no estimate extracted | 2 studies · 4 participants | Ungraded |
Mean exercise tolerance test (after treatment) (min) Shengmai plus usual treatment vs usual treatment alone | no estimate extracted | 1 study · 60 participants | Low Downgraded: imprecision |
Mean change in quality of life Minnesota Living with Heart Failure Questionnaire (MLWHF) score Shengmai plus usual treatment vs usual treatment alone | no estimate extracted | 1 study · 60 participants | Low Downgraded: risk of bias, imprecision |
Mean change in ejection fraction (%) Shengmai plus usual treatment vs usual treatment alone | no estimate extracted | 4 studies · 354 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Mean change in cardiac output (L/min) Shengmai plus usual treatment vs usual treatment alone | no estimate extracted | 4 studies · 360 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Mean change in stroke volume (mL) Shengmai plus usual treatment vs usual treatment alone | no estimate extracted | 3 studies · 240 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Change in cardiac index (L/min*m²) Shengmai plus usual treatment vs usual treatment alone | no estimate extracted | 2 studies · 160 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Hospitalization/rehospitalization Shengmai plus usual treatment vs usual treatment alone | no estimate extracted | 12 studies · 858 participants | Ungraded |
Shengmai compared to placebo for heart failure
Population: patients with heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Shengmai vs placebo | no estimate extracted | 3 studies · 106 participants | Ungraded |
Lack of improvement in heart failure (NYHA class improved < I class or worsening of heart failure) NYHA classification grading of cardiac function Shengmai vs placebo | RR 0.22 [0.11, 0.44] | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects Shengmai vs placebo | no estimate extracted | 1 study · 2 participants | Ungraded |
Mean change in exercise test (mins) Treadmill exercise test Shengmai vs placebo | no estimate extracted | 1 study · 18 participants | Low Downgraded: imprecision |
Mean change in ejection fraction (%) Shengmai vs placebo | no estimate extracted | 1 study · 52 participants | Low Downgraded: imprecision |
Mean change in cardiac output (L/min) Shengmai vs placebo | no estimate extracted | 1 study · 52 participants | Low Downgraded: imprecision |
Mean change in cardiac index (L/min*m²) Shengmai vs placebo | no estimate extracted | 1 study · 80 participants | Low Downgraded: imprecision |
Mean change in ECG: Q‐Z Shengmai vs placebo | no estimate extracted | 1 study · 80 participants | Low Downgraded: imprecision |
Hospitalization/ rehospitalization Shengmai vs placebo | no estimate extracted | 3 studies · 106 participants | Ungraded |
Comparison
Population: patients with heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality | no estimate extracted | 7 studies · 494 participants | Ungraded |
Hospitalisation/rehospitalisation | no estimate extracted | 7 studies · 494 participants | Ungraded |
Lack of improvement in heart failure ( NYHA class improved < I class or worsening of heart failure) | RR 0.33 [0.23, 0.47] | 7 studies · 494 participants | Low |
Exercise test (after treatment) | no estimate extracted | 1 study · 60 participants | Low |
Change in Quality of life | no estimate extracted | 1 study · 60 participants | Low |
Change in ejection fraction (%) | no estimate extracted | 4 studies · 354 participants | Low |
Adverse effects | no estimate extracted | 2 studies · 4 participants | Ungraded |
Comparison
Population: patients with heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality | no estimate extracted | 2 studies · 106 participants | Ungraded |
Hospitalisation/rehospitalisation | no estimate extracted | 2 studies · 106 participants | Ungraded |
Lack of improvement in heart failure ( NYHA class improved < I class or worsening of heart failure) | RR 0 [0, 0] | 1 study · 40 participants | Low |
Change in Exercise test (min) | no estimate extracted | 1 study · 18 participants | Low |
Change in Ejection fraction (%) | no estimate extracted | 1 study · 52 participants | Low |
Adverse effects | no estimate extracted | 1 study · 2 participants | Ungraded |
Comparison
Population: patients with heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lack of improvement in heart failure ( NYHA class improved < I class or worsening of heart failure) | RR 0.37 [0.25, 0.54] | 5 studies · 400 participants | Moderate |
CO(cardiac output (L/min) change | no estimate extracted | 2 studies · 220 participants | Low |
SV(stroke volume) (ml) change | no estimate extracted | 1 study · 100 participants | Low |
CI(cardiac index) change | no estimate extracted | 1 study · 100 participants | Low |
EF(eject fraction) change | no estimate extracted | 2 studies · 220 participants | Low |
Cardiothoracic ration change | no estimate extracted | 1 study · 120 participants | Moderate |
Peak E/A | no estimate extracted | 1 study · 120 participants | Moderate |
Comparison
Population: patients with heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HI change | no estimate extracted | 1 study · 80 participants | Moderate |
Q‐Z change | no estimate extracted | 1 study · 80 participants | Moderate |
Q‐B/B‐X change | no estimate extracted | 1 study · 80 participants | Moderate |
SV(stroke volume) (ml) change | no estimate extracted | 1 study · 80 participants | Moderate |
SVI change | no estimate extracted | 1 study · 80 participants | Moderate |
Adz/dtMax change | no estimate extracted | 1 study · 80 participants | Moderate |
CI change | no estimate extracted | 1 study · 80 participants | Moderate |